The merger is complete and the stock will be delisted. Traders holding APGE shares should have already tendered them for the $135.11 cash consideration. Any remaining shares will be converted to the right to receive the merger consideration. There is no further trading opportunity in APGE common stock.
Price Chart
Executive Summary
Apogee Therapeutics has been acquired by AbbVie in a completed all-cash merger valued at approximately $10.9 billion. Shareholders received $135.11 per share in cash, and the company's stock will be delisted from Nasdaq effective September 4, 2026. This 8-K confirms the consummation of the previously announced merger, resulting in a change of control and the termination of all pre-merger equity plans.
Key Facts
- Merger completed on September 3, 2026, with Apogee becoming an indirect wholly owned subsidiary of AbbVie.
- Shareholders received $135.11 per share in cash, valuing the total equity of the transaction at approximately $10.9 billion.
- All outstanding stock options, RSUs, and restricted stock awards were cashed out or converted at the merger consideration.
- All pre-merger directors and executive officers resigned; new directors from Merger Sub were appointed.
- Company common stock will be suspended from trading on Nasdaq on September 4, 2026, with plans to deregister under the Exchange Act.
- The company's 2023 Equity Incentive Plan and 2023 Employee Stock Purchase Plan were terminated.
- Aggregate parachute payment gross-up for named executive officers is capped at $12,500,000.
Financial Impact
Total equity value of $10.9 billion; shareholders received $135.11 per share in cash.
Risk Factors
- No further trading liquidity as the stock is being delisted.
- Appraisal rights may be pursued by shareholders who did not vote in favor and properly demanded appraisal.
- Potential for post-closing adjustments or litigation related to the merger consideration.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-035537 |
| Document: ef20081397_8k.htm | 0001140361-26-035537 |
| Document: ef20081397_ex10-1.htm | 0001140361-26-035537 |
| Document: ef20081397_ex3-1.htm | 0001140361-26-035537 |
| Document: 0001140361-26-035537-index-headers.html | 0001140361-26-035537 |
| Document: 0001140361-26-035537-index.html | 0001140361-26-035537 |
| Document: 0001140361-26-035537.txt | 0001140361-26-035537 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 15-12G | โ | awaiting T+5 | โ | โ |
Sep 3, 2026 29d ago | 25-NSE | $135.06 awaiting T+5 | awaiting T+5 | โ | โ |
Sep 3, 2026 29d ago | 8-K | $135.06 awaiting T+5 | awaiting T+5 | โ | โ |
Aug 11, 2026 7w ago | 8-K | $134.55 $134.71 | โฒ +0.12% | โฒ +0.56% | โ |
Aug 10, 2026 7w ago | 8-K | $134.65 $134.59 | โผ โ0.04% | โฒ +0.00% | โ |
Aug 10, 2026 7w ago | Press Release | $134.65 $134.59 | โผ โ0.04% | โฒ +0.00% | โ |
Aug 6, 2026 8w ago | Institutional Cluster | $134.49 $134.45 | โผ โ0.03% | โผ โ1.24% | โ |
Aug 3, 2026 8w ago | DEFA14A | $134.19 $134.69 | โฒ +0.37% | โฒ +0.47% | โ |
Jul 11, 2026 11w ago | Insider Cluster | $133.82 $134.00 | โฒ +0.13% | โฒ +0.92% | โ |
Jun 26, 2026 13w ago | DEFA14A | $132.61 $133.50 | โฒ +0.67% | โผ โ0.72% | โ |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access